IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Animal health biotechnology companies are at the forefront of a transforming industry, developing innovative products such as advanced vaccines, medications, diagnostics and precision nutrition solutions to address the evolving needs of companion animals and livestock. Consumers are increasingly treating pets like family, driving a willingness to pay premiums for therapies that offer preventive care, improved quality of life and even tailored nutrition based on genetic or microbiome data. At the same time, livestock producers face mounting pressure from population growth, food security demands and climate-related challenges, making disease prevention, herd resilience and sustainable productivity essential. This dual shift, combining emotional investment in pets and economic imperatives for food animals, significantly expands the market for animal health biotech. However, structural volatility in funding, the R&D cycle and regulatory timelines has contributed to revenue declines over the past five years, despite fast-growing end-market demand. In all, revenue growth has weakened, declining at a CAGR of 0.3% to an estimated $11.9 billion over the past five years, including expected growth of 0.9% in 2025.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Animal Health Biotechnology industry in the United States includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released December 2025.
The Animal Health Biotechnology industry in the United States operates under the NAICS industry code OD4023. Animal health biotechnology companies research, develop, test and distribute therapeutic drugs, diagnostic tools and preventive products for livestock and companion animals. Drugs not developed using biological materials or processes are not included in this industry. In addition, companies provide tools that improve farm animal breeding programs. Related terms covered in the Animal Health Biotechnology industry in the United States include transgenic, genetic engineering, cloning, biopharmaceutical, parasiticide, companion animal and bovine spongiform encephalopathy.
Products and services covered in Animal Health Biotechnology industry in the United States include Pharmaceuticals, Anti-infectives and Other.
Companies covered in the Animal Health Biotechnology industry in the United States include Zoetis Inc. and Merck & Co.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Animal Health Biotechnology industry in the United States.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed product and service segmentation, analysis of major markets and international trade data for the for the Animal Health Biotechnology industry in the United States.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Animal Health Biotechnology industry in the United States.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Animal Health Biotechnology industry in the United States. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the Animal Health Biotechnology industry in the United States. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Animal Health Biotechnology industry in the United States. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Animal Health Biotechnology industry in the United States. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Animal Health Biotechnology industry in the United States.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the Animal Health Biotechnology industry in the United States is $11.8bn in 2026.
There are 188 businesses in the Animal Health Biotechnology industry in the United States, which has grown at a CAGR of 2.4 % between 2020 and 2025.
The Animal Health Biotechnology industry in the United States is unlikely to be materially impacted by import tariffs with imports accounting for a low share of industry revenue.
The Animal Health Biotechnology industry in the United States is unlikely to be materially impacted by export tariffs with exports accounting for a low share of industry revenue.
The market size of the Animal Health Biotechnology industry in the United States has been declining at a CAGR of 0.3 % between 2020 and 2025.
Over the next five years, the Animal Health Biotechnology industry in the United States is expected to grow.
The biggest companies operating in the Animal Health Biotechnology industry in the United States are Zoetis Inc. and Merck & Co
Developing animal vaccines and Researching and testing animal medicine are part of the Animal Health Biotechnology industry in the United States.
The company holding the most market share in the Animal Health Biotechnology industry in the United States is Zoetis Inc..
The level of competition is moderate and increasing in the Animal Health Biotechnology industry in the United States.